Enliven Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
ELVN$51.20-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(71,584) | $(37,662) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 297 | 215 |
| Stock-based compensation | 12,914 | 3,191 |
| Non-cash lease expense | 306 | — |
| Amortization of premiums and discounts on marketable securities, net | (4,603) | — |
| Write-off of deferred IPO costs | — | 1,741 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, other current and long-term assets | (3,703) | (1,590) |
| Operating lease liabilities | (310) | 4 |
| Accounts payable | (2,250) | 411 |
| Accrued expenses and other liabilities | 7,664 | 1,613 |
| Net cash used in operating activities | (61,269) | (32,077) |
| Cash flows from investing activities: | ||
| Maturities of marketable securities | 120,000 | — |
| Purchases of marketable securities | (268,263) | — |
| Purchases of property and equipment | (149) | (612) |
| Net cash used in investing activities | (148,412) | (612) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 399 | 591 |
| Payment of deferred offering costs related to the Merger / initial public offering | — | (2,390) |
| Payment of deferred offering costs related to the Sales Agreement | (563) | — |
| Proceeds from the Financing Transaction, net of issuance costs | 161,365 | — |
| Cash acquired in connection with the reverse recapitalization | 81,821 | — |
| Payment of reverse recapitalization transaction costs | (8,736) | — |
| Net cash provided by (used in) financing activities | 234,286 | (1,799) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 24,605 | (34,488) |
| Cash, cash equivalents and restricted cash at the beginning of the period | 75,590 | 110,078 |
| Cash, cash equivalents and restricted cash at the end of the period | $100,195 | $75,590 |
| Components of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $100,141 | $75,536 |
| Restricted cash | 54 | 54 |
| Total cash, cash equivalents and restricted cash | $100,195 | $75,590 |
| Supplemental disclosure of non-cash operating activities: | ||
| Lease liabilities obtained in exchange for right-of-use assets | $— | $387 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Conversion of convertible preferred stock to common stock | $149,749 | $— |
| Deferred offering costs related to the Merger included in accounts payable and accrued expenses and other current liabilities | $— | $1,846 |
| Receivables from stock option exercises included in prepaid expenses and other current assets | $76 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.